1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 治療タイプ別スニペット
3.2. 投与経路別スニペット
3.3. 患者タイプ別スニペット
3.4. 販売チャネル別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 合併症を伴う気管支痙攣の有病率の上昇
4.1.1.2. 市場参入企業による製品開発活動の活発化
4.1.2. 阻害要因
4.1.2.1. サプライチェーンの不一致
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. 価格分析
5.3. 規制分析
5.4. アンメット・ニーズ
5.5. PESTEL分析
5.6. 特許分析
5.7. SWOT分析
5.8. 疫学
6. 治療タイプ別
6.1. はじめに
6.1.1. 治療タイプ別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数（治療タイプ別
6.2. 気管支拡張薬*市場
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.2.3. β2アゴニスト
6.2.3.1. アルブテロール
6.2.3.2. サルメテロール
6.2.3.3. その他
6.2.4. 抗コリン薬
6.2.4.1. イプラトロピウム臭化物
6.2.4.2. 臭化チオトロピウム
6.2.4.3. その他
6.2.5. キサンチン誘導体
6.3. ステロイド
6.4. ロイコトリエン拮抗薬
6.5. その他
7. 投与経路別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）、投与経路別
7.1.2. 市場魅力度指数（投与経路別
7.2. 経口*剤
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 吸入
7.4. その他
8. 患者タイプ別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）、患者タイプ別
8.1.2. 市場魅力度指数（患者タイプ別
8.2. 小児科*市場
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 大人
8.4. 高齢者
9. 流通チャネル別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.1.2. 市場魅力度指数（流通チャネル別
9.2. 病院薬局
9.2.1. 序論
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 小売薬局
9.4. オンライン薬局
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 主な地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.2.4. 市場規模分析および前年比成長率分析（%）、投与経路別
10.2.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
10.2.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.2.7. 市場規模分析および前年比成長率分析（%）, 国別
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主な地域別ダイナミクス
10.3.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.3.4. 市場規模分析および前年比成長率分析（%）、投与経路別
10.3.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
10.3.6. 市場規模分析および前年比成長率分析（%）：流通チャネル別
10.3.6.1. 市場規模分析および前年比成長率分析（%）, 国別
10.3.6.2. ドイツ
10.3.6.3. イギリス
10.3.6.4. フランス
10.3.6.5. イタリア
10.3.6.6. スペイン
10.3.6.7. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.4.4. 市場規模分析および前年比成長率分析（%）、投与経路別
10.4.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
10.4.6. 市場規模分析および前年比成長率分析（%）：流通チャネル別
10.4.6.1. 市場規模分析および前年比成長率分析（%）, 国別
10.4.6.2. ブラジル
10.4.6.3. アルゼンチン
10.4.6.4. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.5.4. 市場規模分析および前年比成長率分析（%）、投与経路別
10.5.5. 市場規模分析および前年比成長率分析（%）、患者タイプ別
10.5.6. 市場規模分析および前年比成長率分析（%）：流通チャネル別
10.5.7.
10.5.7.1. 市場規模分析および前年比成長率分析（%）, 国別
10.5.7.2. 中国
10.5.7.3. インド
10.5.7.4. 日本
10.5.7.5. 韓国
10.5.7.6. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 主な地域別ダイナミクス
10.6.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.6.4. 市場規模分析および前年比成長率分析（%）、投与経路別
10.6.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
10.6.6. 市場規模分析および前年比成長率分析（%）：流通チャネル別
11. 競合情勢
11.1. 競争シナリオ
11.2. 市場ポジショニング／シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Teva Pharmaceuticals USA, Inc.*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. Cipla.
12.3. GSK plc.
12.4. Nephron Pharmaceuticals Corporation.
12.5. Boehringer Ingelheim International GmbH.
12.6. Sandoz AG
12.7. AstraZeneca.
12.8. Organon group of companies.
12.9. Viatris Inc.
12.10. Lupin Pharmaceuticals, Inc. (*リストは除外)
13. 付録
13.1. 会社概要とサービス
13.2. お問い合わせ
The Global Bronchial Spasm Market reached US$ 424.36 million in 2023 and is expected to reach US$ 650.05 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.
Bronchial spasm, also known as bronchospasm, is a sudden contraction of bronchial smooth muscles causing the narrowing of bronchi. Allergens usually trigger a cascade of inflammatory or excessive muscle contraction events, that result in bronchospasm. The most common symptoms are wheezing and cough, which range from mild to severe. The incidence of bronchospasm is higher in patients with conditions such as asthma, COPD, emphysema, bronchitis, and other inflammatory conditions related to the airway tract.
Market Dynamics: Drivers
Rising prevalence of bronchospasm with associated comorbidities
Bronchial spasms can occur in anyone but are more prevalent among patients with associated co-morbidities such as asthma and COPD. Bronchospasm is one of the major symptoms in patients with these conditions, and as their prevalence grows, the patient population experiencing bronchospasm concurrently rises, creating a demand for therapeutics.
For instance, as per the Global Burden of Asthma study published in the Journal of Asthma and Allergy in October 2023, the prevalence of asthma in Asia was 3.44%, 3.67% in Africa, 4.90% in South America, 5.69% in Europe, 8.29% in North America and 8.33% in Oceania. Among the global asthmatic population globally, 26.70% had severe asthma, 30.99% had eosinophilic asthma, 48.95% had allergic rhinitis, and 7.0% to 25.40% had nasal polyps.
Among this prevalent population, the risk of hypersensitivity reactions such as bronchospasm highly increases if they take Non-steroidal anti-inflammatory drugs, or undergo surgery under general anesthesia. As per the New Zealand Medicine and Medical Device Safety Authority, 8 to 20% of asthmatics experience bronchospasm within 20 minutes to 3 hours after the ingestion of NSAIDs. This is termed Aspirin-induced asthma and can be fatal in some patient populations.
As the population ages, the incidence of NSAID administration may increase to alleviate age-related painful conditions, which may exacerbate bronchospasm. Hence the rising prevalence of asthma and COPD may contribute to increased incidence of bronchospasm, propelling the treatment market growth positively.
Restraints
The market for bronchial spasms is restrained by several factors such as side effects associated with the use of corticosteroids and bronchodilators, higher chances of misdiagnosis which may lead to improper treatment approaches, as well as supply chain discrepancies and drug shortages etc.
Market Segment Analysis
The global bronchial spasm market is segmented based on treatment type, route of administration patient type, distribution channel, and region.
Bronchodilators in the treatment type segment accounted for approximately 56./4% of the global bronchial spasm market share
Bronchodilators are a group of medications, that act on bronchial smooth muscles and relax them causing a dilatory effect and clearing the obstruction in the airway passage. There are several classes of bronchodilators, which majorly include beta-2 receptor agonists, anticholinergics, and xanthine derivatives. Beta-2 receptor agonists include albuterol (salbutamol) and salmeterol, these are termed short-acting bronchodilators that provide immediate relief to the patient. The other class of drugs- anticholinergics, including ipratropium and triotropium, are long-acting bronchodilators that provide long-term relief to patients.
These bronchodilators especially beta-2 receptor agonists are widely used during the acute attacks of bronchospasm and are recommended, for first-line use. As per the National Centre for Biotechnology Information article published in January 2024, Albuterol is the first line agent approved in the U.S. by the FDA to treat and prevent acute or severe bronchospasm. Post approval, many companies have developed and launched their products for clinical use all across the globe. At present several branded versions have lost their patent exclusivity, and there is a surge of generic bronchodilators in the market.
Market Geographical Share
North America dominates the global bronchial spasm market with a share of 43..5% in 2023, and growing at a CAGR of XX% in the forecast period.
North America dominates the global bronchial spasm market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, and increasing prevalence, etc.
For instance, according to the Asthma and Allergy Foundation of America's recent updates in April 2024, Over 27 million people in the U.S. have asthma, which equals 1 in 12 people. Moreover, it is the leading chronic disease in children accounting for approximately 4.5 million cases. As per the Center for Disease Control and Prevention, in 2022, approximately 8.7% of U.S. adults above 18 years of age are living with Asthma, and 6.2% of children below 18 years of age are living with asthma. Among these asthmatic patients, the incidence of bronchospasm is also higher.
Hence, considering these factors, along with the epidemiological data and sales figures by market leaders, North America is designated as a dominant region in the global market.
Market Segmentation
By Treatment Type
Bronchodilators
Beta 2 Agonists
Albuterol
Salmeterol
Others
Anticholinergics
Ipratropium Bromide
Tiotropium Bromide
Others
Xanthine Derivatives
Steroids
Leukotriene Antagonists
Others
By Route of Administration
Oral
Inhalational
Others
By Patient Type
Pediatrics
Adults
Geriatrics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market
Competitive Landscape
The major players in the bronchial spasm market include Teva Pharmaceuticals USA, Inc., Cipla., GSK plc., Nephron Pharmaceuticals Corporation., Boehringer Ingelheim International GmbH., Sandoz AG, AstraZeneca., Organon group of companies., Viatris Inc. and Lupin Pharmaceuticals, Inc. among others.
Why Purchase the Report?
To visualize the global bronchial spasm
Market Segmentation based on treatment type, route of administration, patient type, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of bronchial spasm market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global bronchial spasm market report would provide approximately 70 tables, 63 figures, and 212 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by Patient Type
3.4. Snippet by Distribution Channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of bronchospasm with associated comorbidities
4.1.1.2. Rising product development activities by market players
4.1.2. Restraints
4.1.2.1. Supply chain discrepancies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Unmet Needs
5.5. PESTEL Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. Epidemiology
6. By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Bronchodilators*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Beta 2 Agonists
6.2.3.1. Albuterol
6.2.3.2. Salmeterol
6.2.3.3. Others
6.2.4. Anticholinergics
6.2.4.1. Ipratropium Bromide
6.2.4.2. Tiotropium Bromide
6.2.4.3. Others
6.2.5. Xanthine Derivatives
6.3. Steroids
6.4. Leukotriene Antagonists
6.5. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Inhalational
7.4. Others
8. By Patient Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Pediatrics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
8.4. Geriatrics
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.2. Germany
10.3.6.3. UK
10.3.6.4. France
10.3.6.5. Italy
10.3.6.6. Spain
10.3.6.7. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.2. Brazil
10.4.6.3. Argentina
10.4.6.4. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7.
10.5.7.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.2. China
10.5.7.3. India
10.5.7.4. Japan
10.5.7.5. South Korea
10.5.7.6. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Teva Pharmaceuticals USA, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Cipla.
12.3. GSK plc.
12.4. Nephron Pharmaceuticals Corporation.
12.5. Boehringer Ingelheim International GmbH.
12.6. Sandoz AG
12.7. AstraZeneca.
12.8. Organon group of companies.
12.9. Viatris Inc.
12.10. Lupin Pharmaceuticals, Inc. (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us
❖ 世界の気管支痙攣市場に関するよくある質問(FAQ) ❖
・気管支痙攣の世界市場規模は？
→DataM Intelligence社は2023年の気管支痙攣の世界市場規模を4億2,436万米ドルと推定しています。
・気管支痙攣の世界市場予測は？
→DataM Intelligence社は2031年の気管支痙攣の世界市場規模を6億5,005万米ドルと予測しています。
・気管支痙攣市場の成長率は？
→DataM Intelligence社は気管支痙攣の世界市場が2024年～2031年に年平均5.6%成長すると予測しています。
・世界の気管支痙攣市場における主要企業は？
→DataM Intelligence社は「Teva Pharmaceuticals USA, Inc.、Cipla.、GSK plc.、Nephron Pharmaceuticals Corporation.、Boehringer Ingelheim International GmbH.、Sandoz AG、AstraZeneca.、Organon group of companies.、Viatris Inc.、Lupin Pharmaceuticals, Inc.など ...」をグローバル気管支痙攣市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
